Aurora Cannabis (ACB) vs Orchestra BioMed (OBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Aurora Cannabis (ACB) over the past year, gaining 45.3% versus a loss of 1.2%. Over five years, OBIO leads with a -33.3% price change compared with -93.9% for ACB. Orchestra BioMed is the larger company by market cap ($517.9 million vs $273.5 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACB | OBIO |
|---|---|---|
| Share price | $4.16 | $6.58 |
| Market cap | $273.50M | $517.88M |
| 1-day change | -2.35% | -6.00% |
| YTD return | -1.42% | +58.55% |
| 1-year return | -1.19% | +45.25% |
| 5-year return | -93.87% | -33.27% |
| EPS (TTM) | $-0.19 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $33.48M |
| Revenue growth (YoY) | — | +1169.22% |
| Net income (latest FY) | — | $-52.70M |
| Gross margin | — | 99.43% |
| Operating margin | — | -154.73% |
| Net margin | — | -157.40% |
| 52-week high | $6.36 | $7.83 |
| 52-week low | $2.56 | $3.46 |
| Distance from 52-week high | -34.59% | -15.91% |
| Analyst consensus | underperform | strong_buy |
| Avg. price target upside | — | +101.98% |
| Average volume | 1.31M | 420.19K |
| Shares outstanding | 65.74M | 78.70M |
| Employees | 1,028 | 86 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OBIO has outperformed ACB by 46.4 percentage points over the past year.
About Aurora Cannabis
ACB stock →Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products.
Health Care · Medicinal Chemicals and Botanical Products · 1,028 employees
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
ACB vs OBIO FAQ
Which is bigger, Aurora Cannabis or Orchestra BioMed?
Orchestra BioMed (OBIO) is larger, with a market capitalization of $517.88M compared with $273.50M for Aurora Cannabis (ACB).
Which stock has performed better over the past year, ACB or OBIO?
OBIO returned +45.25% over the past 12 months, compared with -1.19% for ACB (price return, excluding dividends). Past performance does not predict future results.
Are Aurora Cannabis and Orchestra BioMed in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.